EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent by Mottet, Nicolas et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/102868/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Mottet, Nicolas, Bellmunt, Joaquim, Bolla, Michel, Briers, Erik, Cumberbatch, Marcus G., De
Santis, Maria, Fossati, Nicola, Gross, Tobias, Henry, Ann M., Joniau, Steven, Lam, Thomas B.,
Mason, Malcolm David, Matveev, Vsevolod B., Moldovan, Paul C., van den Bergh, Roderick C.N.,
Van den Broeck, Thomas, van der Poel, Henk G., van der Kwast, Theo H., Rouvière, Olivier,
Schoots, Ivo G., Wiegel, Thomas and Cornford, Philip 2017. EAU-ESTRO-SIOG guidelines on
prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. European
Urology 71 (4) , pp. 618-629. 10.1016/j.eururo.2016.08.003 file 
Publishers page: http://dx.doi.org/10.1016/j.eururo.2016.08.003
<http://dx.doi.org/10.1016/j.eururo.2016.08.003>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
1 
 
 
 
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis and local treatment 
with curative intent 
 
Nicolas Motteta, Joaquim Bellmuntb, Michel Bollac, Erik Briersd, Marcus G. Cumberbatche, 
Maria De Santisf, Nicola Fossatig, Tobias Grossh, Ann M. Henryi, Steven Joniauj, Thomas 
Lamk, Malcolm D. Masonl, Seva Matveevm, Paul Moldovann, Roderick C.N. van den Bergho, 
Henk G. van der Poelp, Theo H. van der Kwastq, Olivier Rouvièren, Ivo G. Schootsr, Thomas 
Wiegels, Philip Cornfordt. 
 
aDepartment of Urology, University hospital, St. Etienne, France;  
bBladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical 
School, Boston, MA, USA; 
cDepartment of Radiation Therapy, C.H.U. Grenoble, Grenoble, France; 
dHasselt, Belgium;  
eAcademic Urology Unit, University of Sheffield, Sheffield; 
fUniversity of Warwick, Cancer Research Unit, Coventry, UK; 
gUnit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; 
Università Vita-Salute San Raffaele, Milan, Italy; 
hDepartment of Urology, University of Bern, Inselspital, Bern, Switzerland; 
iLeeds Cancer Centre, St James's University Hospital, Leeds, UK; University of Leeds, Leeds, 
UK; 
jDepartment of Urology, University Hospitals Leuven, Leuven, Belgium;  
kAcademic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, 
Aberdeen Royal Infirmary, Aberdeen, UK; 
lVelindre Hospital, Cardiff, UK;  
mDepartment of Onco-Urology, Cancer Research Centre, Moscow, Russia; 
nHospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France. 
oDepartment of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands; 
pDepartment of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 
qDepartment of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands; 
rDepartment of Radiology and Nuclear Medicine, Erasmus MC University Medical Centre, 
Rotterdam, The Netherlands; 
sDepartment of Radiation Oncology, University Hospital Ulm, Ulm, Germany; 
tRoyal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK. 
 
Corresponding author 
Nicolas Mottet, M.D., Ph.D.  
Department of Urology 
University hospital 
St. Etienne, France 
Telephone : +33 477828331   
Fax : +33 477517179   
Email: nicolas.mottet@chu-st-etienne.fr  
 
Word count 
2 
 
Abstract: 486 words 
Body text: 4401 words  
 
Key words: prostate cancer; localised; EAU Guidelines; screening; diagnosis; staging; 
treatment; radical prostatectomy, radiation therapy, androgen deprivation 
 
 
 
Abstract 
Objective: To present a summary of the 2016 version of the European Association of 
Urology (EAU) guidelines on screening, diagnosis, and local treatment with curative intent of 
clinically localised prostate cancer. 
Evidence acquisition: The Working Panel performed a literature review of the new data 
(2013-2015). The guidelines were updated and the levels of evidence and/or grades of 
recommendation were added based on a systematic review of the evidence 
Evidence synthesis: BRCA2 mutations have been added as risk factors for early and 
aggressive disease.  In addition to the Gleason score the 5-tiered 2014 ISUP grading system 
should now be provided. Systematic screening is still not recommended. Instead, an 
individual risk adapted strategy following a detailed discussion and taking into account the 
patient’s wishes and life expectancy must be considered. An early PSA test, the use of a risk 
calculator or one of the promising biomarker tools are being investigated and might be able to 
limit the over-detection of insignificant PCa. Breaking the link between diagnosis and 
treatment may lower the over-treatment risk. A multiparametric MRI using standardised 
reporting cannot rule out systematic biopsy, but nested more robust within the diagnostic 
work-up, it has a key role in local staging. Active surveillance always needs to be discussed 
with very low-risk patients. The place of surgery in high-risk disease and the role of lymph 
node dissection have been clarified, as well as the management of node positive patients. 
Radiotherapy using dose-escalated intensity-modulated technology is a key treatment 
modality with recent improvement in outcome based on increased doses as well as 
combination with hormonal treatment. Moderate hypofractionation is safe, but long-term data 
are still lacking. High-dose-rate brachytherapy represents an interesting way to increase the 
delivered dose. Focal therapy remains experimental as convincing long term outcome results 
are still lacking, in particular for cryosurgery and high-intensity focused ultrasound. 
Conclusion: The knowledge in the field of diagnosis, staging and treatment of localised 
prostate cancer is rapidly evolving. The 2016 EAU guidelines on PCa summarise the most 
recent findings and provide recommendations for clinical practice. These are the first EAU 
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prostate cancer guidelines endorsed by the European Society for Radiotherapy and Oncology 
(ESTRO), and International Society of Geriatric Oncology (SIOG) and reflect the 
multidisciplinary nature of prostate cancer management. A full version is available at the 
EAU office and online at http://uroweb.org/guideline/prostate-cancer/. 
Patient Summary: Prostate Cancer remains the most common cancer diagnosed in men in 
Europe (with the exception of skin cancers). Over the past years, in Northern and Western 
Europe, the number of men diagnosed with prostate cancer has been on the rise. This may be 
due to an increase in opportunistic screening, but also other factors may be involved (diet, 
sexual behaviour, exposure to ultraviolet radiation). The authors propose that men who are 
potential candidates for screening should be engaged in a discussion with their clinician (also 
involving their families/caregivers) so that an informed decision may be made, as part of an 
individualised risk-adapted approach.  
 
Introduction 
The last summary of the European Association of Urology (EAU) guidelines on prostate 
cancer (PCa) was published in 2013 [1]. This paper summarises the new insights/many 
changes that have occurred in the screening, diagnosis and treatment of localised PCa over the 
last 3 years and is based on annual structured literature searches and systematic review as a 
continuous process. Evidence levels and grade of recommendation have been formulated 
according to the general principles of evidence based medicine [2].  
Prostate cancer remains the most common cancer in males in Europe (excluding skin 
cancer). While the incidence of autopsy-detected cancers is roughly the same in different parts 
of the world, the incidence of clinically diagnosed PCa varies widely, being highest in 
Northern and Western Europe (> 200 per 100,000 men) [3]. Besides the increased 
opportunistic screening with PSA, this is suggested to be a consequence of exogenous factors, 
such as diet, chronic inflammation, sexual behaviour, and exposure to ultraviolet radiation [4].  
Metabolic syndrome has been linked with an increased risk of PCa [5], but there is 
insufficient evidence to recommend lifestyle changes or a modified diet to lower this risk. In 
hypogonadal men, testosterone therapy is not associated with an increased PCa risk [6]. No 
drugs or food supplements have been approved for PCa prevention. 
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Apart from age and African-American origin, family history of PCa (both paternal and 
maternal [7]) is a well-established risk factor. If one first-degree relative has PCa, the risk is at 
least doubled. It increases by 5 – 11 times when two or more first-line relatives are affected 
[8]. About 9% of men with PCa have truly hereditary disease, which is associated with an 
onset six to seven years earlier than spontaneous cases, but the biology does not differ. The 
only exception are carriers of the rare BRCA2 germline abnormality, who seem to have an 
increased risk of early-onset PCa with aggressive behaviour [9-11].  
 
Classification 
The 2009 TNM classification for staging of PCa and the EAU risk group classification are 
recommended (Table 1). The latter classification is based on the grouping of patients with a 
similar risk of biochemical recurrence (BCR) after local treatment. 
 
Table 1:  EAU risk groups for biochemical recurrence of localised and locally advanced prostate 
Cancer 
 
Low-risk Intermediate-risk High-risk 
Definition 
PSA < 10 ng / mL 
and GS < 7 
and cT1-2a 
PSA 10-20 ng /mL 
or GS 7 
or cT2b 
PSA > 20 ng / mL 
or GS > 7 
or cT2c 
any PSA 
any GS  
cT3-4 or cN+ 
Localised Locally advanced 
 
GS = Gleason score; PSA = prostate-specific antigen. 
 
 
The ISUP 2005 modified Gleason score (GS) is the recommended PCa grading 
system. The biopsy GS consists of the Gleason grade of the most extensive pattern plus the 
highest grade, regardless of its extent. In radical prostatectomy (RP) specimens, the GS is 
determined differently: a pattern comprising ≤ 5% of the cancer volume is not incorporated in 
the GS but its proportion should be reported separately if it is grade 4 or 5.  
The 2014 ISUP Gleason Grading Conference on Cleason Grading of Prostate Cancer 
[12] adopted the concept of grade groups of PCa, in order to align PCa grading with the 
grading of other carcinomas. Furthermore, it eliminates the anomaly that the most highly 
differentiated PCas have a GS 6 and highlights the clinical differences between GS 7 (3 + 4) 
and 7 (4 + 3) (Table 2). 
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Table 2: International Society of Urological Pathology 2014 grade groups* 
 
Gleason score Grade group 
2-6 1 
7 (3 + 4) 2 
7 (4 + 3) 3 
8 (4 + 4) or (3+ 5) or (5 + 3) 4 
9-10 5 
 
*Grade groups can now be reported in addition to the overall or global Gleason score of a prostate 
biopsy or radical prostatectomy 
 
Screening and early detection 
Screening for PCa remains one of the most controversial topics in the urological literature. A 
Cochrane review [13] suggests that PSA screening is associated with an increased diagnosis 
rate (RR: 1.3; 95% CI: 1.02-1.65) and the detection of more localised (RR: 1.79; 95% CI: 
1.19-2.70) and less advanced disease (T3-4, N1, M1) (RR: 0.80; 95% CI: 0.73-0.87). 
However neither overall survival (OS) (RR: 1.00; 95% CI: 0.96-1.03) nor cancer-specific 
survival (CSS) benefits were observed (RR: 1.00; 95% CI: 0.86-1.17). Moreover, screening 
was associated with over-diagnosis and over-treatment. All these considerations have led to a 
strong recommendation against systematic population-based screening in Europe and the 
USA. And yet, the European Randomized Study of (population-based) Screening for Prostate 
Cancer (ERSPC) showed a reduction in PCa mortality in the screening arm (RR: 0.8; 95% CI: 
0.70-1.03) after a median follow-up of 9 years. Updated results from the ERSPC at 13 years 
of follow-up showed an unchanged cancer-specific mortality reduction 0.79 (0.69-0.91) [14], 
but the number-needed-to-screen (n=781) and to treat (n=27) to avoid one death from PCa 
decreased, and is now below the number-needed-to-screen in breast cancer trials [15] (Table 
3). Furthermore, the uptake of the 2012 USPSTF recommendations against PSA testing has 
been associated with a substantial number of men with aggressive disease being missed [16]. 
Finally, a comparison of systematic and opportunistic screening suggested over-diagnosis and 
mortality reduction by systematic screening versus a higher over-diagnosis with at best a 
marginal survival benefit after opportunistic screening [17].  
 
Table 3:  Follow-up data from the ERSPC study [14] 
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Years of follow-up Number needed to screen* Number needed to treat* 
9 1,410 48 
11 979 35 
13 781 27 
 
* Number of men needed to screen or treat in order to avoid the death of disease of one man. 
ERSPC = European Randomized Study of Screening.  
 
 
Targeting men at higher risk of PCa might reduce the number of unnecessary biopsies. 
These include men above 50 years of age, or above 45 for African-American men or those 
with a family history of PCa. In addition, men with a PSA > 1 ng/mL at 40 years and > 2 
ng/mL at 60 years [18, 19] are at increased risk of PCa metastasis or death several decades 
later. Risk calculators developed from cohort studies may also be useful in reducing the 
number of unnecessary biopsies. None have clearly shown superiority over another or can be 
considered as optimal [20].  
Optimal follow-up intervals for PSA testing and digital rectal examination (DRE) are 
unknown. A 2-year interval for men at increased risk based on PSA level is reasonable, while 
it could be extended to up to 8-years for those not at risk. The age at which to stop PSA 
testing should be based on an individual’s life expectancy where co-morbidity is at least as 
important as age [21]. Men who have less than a 15-year life expectancy are unlikely to 
benefit. 
Application of all the currently available tools will still not rule out over-diagnosis. 
Breaking the link between diagnosis and active treatment is the only way to decrease the risk 
of over-treatment, while still maintaining the potential benefit of individual early diagnosis 
for men requesting it (Table 4).  
 
Table 4: Guidelines for screening and early detection 
 
Recommendation  LE GR 
Do not subject men to PSA testing without counselling them on the potential risks and 
benefits. 
3  B 
Offer an individualised risk-adapted strategy for early detection to a well-informed man 
with a good performance status and a life-expectancy of at least 10-15 years. 
3  
 
B 
Offer PSA testing in men at elevated risk of having PCa: 
•  men > 50 years of age 
•  men > 45 years of age and a family history of PCa 
•  African-Americans > 45 years of age 
2b A 
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•  men with a PSA level of > 1 ng/mL at 40 years of age 
•  men with a PSA level of > 2 ng/mL at 60 years of age 
Offer a risk-adapted strategy (based on initial PSA level), with follow-up intervals of 2 
years for those initially at risk: 
•  men with a PSA level of > 1 ng/mL at 40 years of age 
•  men with a PSA level of > 2 ng/mL at 60 years of age 
Postpone follow-up to 8 years in those not at risk. 
3 C 
Decide on the age at which early diagnosis of PCa should be stopped based on life 
expectancy and performance status; men who have a life-expectancy of < 15-years are 
unlikely to benefit. 
3 A 
 
PCa = prostate cancer; PSA = prostate-specific antigen.  
 
 
Diagnosis 
Prostate cancer is usually suspected on the basis of digital rectal exam (DRE) and/or an 
elevated PSA. Definitive diagnosis depends on histopathological verification. Abnormal DRE 
is an indication for biopsy, but as an independent variable, PSA is a better predictor of cancer 
than either DRE or transrectal ultrasound (TRUS). PSA is a continuous parameter, with 
higher levels indicating greater likelihood of PCa, precluding an optimal PSA threshold for 
detecting non-palpable but clinically significant PCa. A minor PSA elevation alone should be 
confirmed after a few weeks under standardised conditions (i.e., no ejaculation, 
manipulations, and urinary tract infections) in the same laboratory before considering a 
biopsy. The empiric use of antibiotics to lower PSA in an asymptomatic patient is not 
recommended [22]. 
Free/total (f/t) PSA ratio stratifies the risk of PCa in men with 4-10 ng/mL total PSA 
and a previous negative biopsy but may be affected by several pre-analytical and clinical 
factors (e.g. instability of free PSA at 4°C and room temperature, variable assay 
characteristics, and large concomitant benign prostatic hyperplasia [BPH]). Novel assays for 
risk stratification measuring a panel of kallikreins including the Prostate Health Index (PHI) 
test, and the four kallikrein (4K) score test are developed to reduce the number of unnecessary 
biopsies in men with a PSA between 2-10 ng/mL. Prospective multicentre studies 
demonstrated that both tests out-performed f/t PSA for PCa detection [23, 24]. Nevertheless a 
formal comparison of these new tests is lacking. 
 
Prostate biopsy 
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Transrectal ultrasound (TRUS)-guided biopsy using an 18G biopsy needle and a periprostatic 
block is the standard of care. When the same number of cores are taken, both transrectal and 
transperineal approaches have comparable detection rates [25, 26]. 
Ten to twelve core biopsies should be taken from the peripheral gland, bilateral from 
apex to base, as far posterior and lateral as possible. Additional cores should be obtained from 
DRE/TRUS suspicious areas. Oral or intravenous quinolones remain standard prophylactic 
antibiotics, in spite of the increasing resistance to quinolones, which is associated with a rise 
in severe and potentially lethal infectious complications [27]. Other biopsy complications 
include haematospermia (37%), heamaturia lasting more than 1 day (14.5%), rectal bleeding 
lasting < 2 days (2.2%). Each biopsy site should be reported individually, including type of 
carcinoma, its location, the ISUP 2005 GS and extent. ISUP 2014 grade should be given as a 
global grade, taking into account the Gleason grade(s) of cancer foci in all biopsy sites. If 
identified, intraductal carcinoma, lymphovascular invasion, perineural invasion and 
extraprostatic extension must each be reported.  
 
Following an initial negative biopsy, the indications for repeat biopsy are summarised in 
Table 5.  
 
Table 5: Indications for re-biopsy after a negative biopsy and the associated risk to find a prostate 
cancer 
 
 Associated PCa risk  
Rising and/or persistently elevated PSA   
Suspicious DRE 5-30%  
Atypical small acinar proliferation (i.e., atypical glands 
suspicious for cancer)  
40%  
EǆteŶsiǀe ;ŵultiple ďiopsǇ sites, i.e., ш ϯͿ high grade 
prostatic intraepithelial neoplasia (HGPIN) 
̴ 30%  
Few atypical glands immediately adjacent to high grade PIN 
(i.e., PINATYP) 
50%  
Intraductal carcinoma as a solitary finding > 90% (mainly high-grade PCa)  
Positive multiparametric MRI  34 – 68% 
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DRE = digital rectal examination; PCa = prostate cancer; PIN = prostatic intraepithelial neoplasia; MRI 
= magnetic resonance imaging; PSA = prostate-specific antigen. 
 
Many single-centre studies suggest that multiparametric MRI (mpMRI) can reliably 
detect aggressive tumours with a negative (NPV) and positive predictive value (PPV) ranging 
from 63 to 98% and from 34 to 68%, respectively [28]. The combination of systematic and 
targeted biopsies (MRI-Tbx) may also better predict the final GS [29]. As a result, some 
authors proposed performing systematic mpMRI before prostate biopsy [30, 31]. One meta-
analysis suggested that MRI-Tbx had a higher detection rate of clinically significant PCa 
compared to TRUS biopsy (sensitivity 0.91 vs. 0.76) and a lower rate of detection of 
insignificant PCa (sensitivity 0.44 vs. 0.83). However this benefit was restricted to the repeat 
biopsy subgroup [32]. Three more recent RCTs restricted to the initial biopsy, yielded 
contradictory results regarding the added value of MRI-Tbx combined with systematic 
biopsies [33, 34]. Major limitations of mpMRI are its inter-observer variability and the 
heterogeneity in definitions of positive and negative examinations. The first version of the 
Prostate Imaging Reporting and DataSystem (PIRADS) scoring system did not improve inter-
observer variability as compared to subjective scoring [35]. An updated version (PIRADS 
V2) needs to be evaluated further [36]. 
 
 
Staging of prostate cancer 
The decision to proceed with further staging work-up is guided by which treatment options 
are available taking into account the patient’s preference and comorbidity. A summary of the 
guidelines is presented in Table 6.  
 
Table 6: Guidelines for staging of prostate cancer 
 
Any risk group staging  LE GR 
Do not use CT and TRUS for local staging. 2a  A 
 
 
Low-risk localised PCa  LE GR 
Do not use additional imaging for staging purposes. 2a  A 
 
 
Intermediate-risk PCa  LE GR 
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In predominantly Gleason pattern 4, metastatic screening, include at least a cross-
sectional abdominopelvic imaging and a CT/MRI and bone-scan for staging purposes. 
2a  A* 
In predominantly Gleason pattern 4, use prostate mpMRI for local staging and 
metastatic screening. 
2b A 
 
 
High-risk localised PCa/ High-risk locally advanced PCa  LE GR 
Use prostate mpMRI for local staging. 2b A 
Perform metastatic screening including at least cross-sectional abdominopelvic 
imaging and a bone-scan. 
2a A 
 
CT = computed tomography; mpMRI = multiparametric magnetic resonance imaging; PCa = prostate cancer; 
PET = positron emission tomography; TRUS = transrectal ultrasound. 
 
 
Primary local treatment  
Management decisions should be made after all options have been discussed in a 
multidisciplinary team including urologists, radiation oncologists, medical oncologists, 
pathologists and radiologists, and after the balance of benefits and side effects of each 
treatment modality has been considered together with the patient. 
 
Active Surveillance and Watchful Waiting 
Active surveillance (AS) aims to reduce over-treatment in men with very-low risk PCa, 
without compromising opportunities for cure, while watchful waiting (WW) is a conservative 
management for frail patients until the possible development of clinical progression, 
necessitating symptomatic treatment. The major differences between these 2 modalities are 
detailed in Table 7. 
 
Table 7: Definitions of active surveillance and watchful waiting 
 
 Active surveillance (AS) Watchful waiting (WW) 
Treatment intent Curative Palliative 
Follow-up Predefined schedule Patient-specific 
Assessment/markers used DRE, PSA, re-biopsy, mpMRI Not predefined 
Life expectancy > 10 years < 10 years 
Aim Minimise treatment-related 
toxicity without compromising 
survival 
Minimise treatment-related 
toxicity 
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Comments Only for low-risk patients Can apply to patients with all 
stages 
 
DRE = digital rectal examination; PSA = prostate-specific antigen; mpMRI = multiparametric magnetic 
resonance imaging. 
 
 
Mortality from untreated screen-detected PCa in patients with GS 5-7 can be as low as 7% at 
15 years follow-up [37]. A randomised trial was unable to show an OS and CSS difference at 
10 years between RP or WW in 731 men with screen-detected clinically organ-confined PCa 
[38]. Only patients with intermediate risk or with a PSA > 10 ng/mL had a significant OS 
benefit from RP (HR: 0.69. 95% CI: 0.49-0.98) and 0.67 95% CI: 0.48-0.94) respectively. A 
population based analysis of 19,639 patients aged > 65 years who were not given curative 
treatment found that in men having a Charlson Comorbidity Index score > 2, tumour 
aggressiveness had little impact on OS at 10 years [39]. These data highlight the potential role 
of WW in some patients with an individual life expectancy of less than 10 years.  
A systematic review has summarised the available data on AS [40]. There is 
considerable heterogeneity between studies regarding patient selection, follow-up policies and 
when active treatment should be instigated. Selection criteria for AS include: clinical T1c or 
T2a, PSA < 10 ng/mL and PSA density < 0.15 ng/mL/cc (even if still controversial [41]), < 2 
- 3 positive cores with < 50% cancer involvement of every positive core, and GS 6. Men with 
extraprostatic extension or lymphovascular invasion are exclusion criteria for AS [42]. Re-
biopsy to exclude Gleason sampling error is considered important, [41] and mpMRI 
combined with targeted prostate biopsy demonstrated additional value in reclassification to 
high-grade PCa [43]. Its major role is furthermore based on its high NPV value for upgrading 
and to exclude anterior prostate lesions [43]. Follow-up in AS is based on repeat biopsy, [41] 
serial PSA measurements and DRE, but the optimal schedule remains unclear. Strategies how 
to incorporate mpMRI within this follow-up are evolving, but are not established yet. The 
decision to switch to active treatment is based on a change in the inclusion criteria (T-stage 
and biopsy results). The use of a PSA change (especially a PSA-DT < 3 years) remains 
contentious based on its weak link with grade progression. Active treatment may also be 
triggered upon a patient’s request [44].   
 
 
Radical Prostatectomy 
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The goal of RP is eradication of PCa, while preserving continence and, whenever possible, 
potency. It is the only treatment for localised PCa showing a benefit for OS and CSS, 
compared with WW. Patients should not be denied this procedure on the grounds of age alone 
[21] provided they have at least 10 years of life expectancy and are aware that increasing age 
is linked to increased incontinence risk. Nerve-sparing RP can be performed safely in most 
men with localised PCa. High risk of extracapsular extension, such as locally advanced 
disease or any GS > 7 are usual contraindications for a nerve-sparing approach. An externally 
validated nomogram predicting side-specific extraprostatic extension can help guide decision-
making [45]. mpMRI may be helpful for selecting a nerve-sparing approach as it has good 
specificity (0.91 [95% CI: 0.88-0.93]) but low sensitivity (0.57 [95% CI: 0.49-0.64]) for 
detecting microscopic pT3a stages [46]. But the experience of the radiologist remains of 
paramount importance.  
 
Lower rates of positive surgical margins for high-volume surgeons suggest that 
experience and careful attention to surgical details, can improve surgical cancer control [47] 
and lower complication rates.  
 
 There is still no evidence that one surgical approach is better than another (open, 
laparoscopic or robotic), as highlighted in a formal systematic review. Robot-assisted 
prostatectomy (RALP) is associated with lower perioperative morbidity and a reduced 
positive margin rate compared with laparoscopic prostatectomy, although there is 
considerable methodological uncertainty. No real differences exist in cancer-related-, 
continence- or erectile function outcomes [48].  
 
 
 Pelvic lymph node dissection 
The individual risk of finding positive lymph nodes can be estimated using pre-operative 
nomograms such as the Briganti nomogram, which has been externally validated [49]. A risk 
of nodal metastases over 5% is an indication to perform an extended pelvic lymph node 
dissection (ePLND). This includes removal of the nodes overlying the external iliac artery and 
vein, the nodes within the obturator fossa located cranially and caudally to the obturator 
nerve, the nodes medial and lateral to the internal iliac artery, and the nodes overlying the 
common iliac artery and vein up to the ureteral crossing. It is recommended that for each 
region the nodes should be sent separately for pathologic analysis. With this template, 75% of 
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all anatomical landing sites are cleared, resulting in a better staging accuracy as compared to a 
limited pelvic lymph node dissection (lPLND), but at the cost of higher complication rates 
(19.8% vs. 8.2%), mainly related to significant lymphoceles [50].  
In men with positive pelvic nodes (pN+) PCa, early adjuvant ADT has been shown to achieve 
a 10-year CSS rate of 80% [51]. Furthermore, improving local control with pelvic 
radiotherapy combined with ADT appeared to be beneficial in pN1 PCa patients treated with 
an ePLND. Men with minimal-volume nodal disease (< 3 lymph nodes) and GS 7-10 and 
pT3-4 or positive margins as well as men with 3-4 positive nodes were more likely to benefit 
from combined ADT and RT after surgery [52].  
 
  Low-risk PCa: The decision to offer RP should be based upon the probabilities of 
clinical progression, side effects and potential survival benefit. No lymph node dissection is 
needed. 
 
Intermediate-risk, localised PCa: Data from SPCG-4 [53] and a preplanned 
subgroup analysis (PIVOT) [36] highlighted the benefit of RP compared with WW. The risk 
of having positive nodes is 3.7-20.1% [49]. An ePLND should be performed if the estimated 
risk for pN+ exceeds 5% [49]. In all other cases, nodal dissection can be omitted, while 
accepting a low risk of missing positive nodes. 
 
High-risk and locally advanced PCa: These patients are at an increased risk of PSA failure, 
need for secondary therapy, metastatic progression and death from PCa. Provided that the 
tumour is not fixed, and not invading the urethral sphincter, RP combined with an ePLND is a 
reasonable first step in a multimodal approach. The estimated risk for pN+ is 15-40% [49]. 
Regarding high-risk PCa patients treated with a multimodal approach, those with a GS 8-10 
prostate confined lesion have a good prognosis after RP. In addition frequent downgrading 
exists between the biopsy and the specimen GS [54]. At 10- and 15-years follow-up the CSS 
is up to 88% and 66%, respectively [55, 56]. A PSA > 20 ng/mL is associated with a CSS at 
10 and 15 years ranging between 83-91% and 71-85%, respectively [55 - 57]. Surgery has 
traditionally been discouraged for cT3N0 PCa, mainly because of the increased risk of 
positive margins and lymph node metastases and/or distant relapse. However, retrospective 
case series demonstrated a CSS at 10- and 15-years between 85-92% and 62-84% 
respectively, while 10-year OS ranged between 76-77% [58]. The overall heterogeneity of 
this high-risk group has been highlighted by a large retrospective multicenter cohort of 1360 
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high-risk patients treated with RP in a multimodal approach [58]. At 10 years, a 91.3% CSS 
was observed. CSS was 95% for those having only 1 risk factor (i.e. GS > 7 or cT > cT2 or 
PSA > 20 ng/mL), 88% for those having a cT3-4 and a PSA > 20 ng/mL, and reduced to 79% 
if all 3 risk factors were present. 
 
Side effects of radical prostatectomy 
Post-operative incontinence and ED are common problems following radical prostatectomy. 
There is no major difference based on the surgical approach with an overall continence rate 
between 89-100% when a robotic procedure was conducted compared with 80-97% for the 
open retropubic approach [59].  
Recently, a prospective, controlled, non-randomised trial of patients treated in 14 
centres was published. At 12 months after robotic surgery, 21.3% were incontinent, as were 
20.2% after open RP. The adjusted OR was 1.08 (95% CI: 0.87-1.34). Erectile dysfunction 
was observed in 70.4% after robotic and 74.7% after open RP. The adjusted OR was 0.81 
(95% CI: 0.66-0.98) [60].  
 
 
Definitive Radiotherapy 
Dose-escalated Intensity-modulated radiotherapy (IMRT), with or without image-guided 
radiotherapy (IGRT), is the gold standard for external beam radiotherapy (EBRT) as it is 
associated with less toxicity compared with 3D conformal (3D-CRT) techniques [61]. 
However, whatever the technique and their degree of sophistication, quality assurance plays a 
major role in the planning and delivery of RT 
 Randomised studies have shown that escalating the dose into the 74-80 Gy range leads 
to a significant improvement in 5-year biochemical disease-free survival [62-65]. In men with 
intermediate- or high-risk PCa there is also evidence to support an OS benefit from a non-
randomised but well conducted propensity matched retrospective analysis covering a total of 
42,481 patients [66]. 
 Biological modeling suggests that prostate cancer may be sensitive to an increased 
dose per fraction resulting in the investigation in randomised trials of hypofractionation 
(HFX). HFX delivered with fewer treatments can increase the convenience for the patient and 
lower costs for the health care system. 
A systematic review concludes that studies investigating the efficacy of moderate 
HFX (2.5 - 4 Gy/fx) delivered with conventional 3D-CRT/IMRT have sufficient follow-up to 
15 
 
support the safety of this therapy, but long-term efficacy data are still lacking [67]. HFX 
requires meticulous quality assurance, excellent image guidance and close attention to organ 
at risk dose-constraints to minimise the long term toxicity risk. Extreme HFX (5-10 Gy/fx) 
where radiation is delivered in 5-7 fractions should still be considered as investigational. 
  
Low-risk PCa: This patient category should be offered dose-escalated IMRT (74-78 
Gy) without ADT. 
 
Intermediate-risk PCa: Patients suitable for ADT should be given combined dose-
escalated IMRT (76-78 Gy) with short-term ADT (4-6 months) [68]. For patients unsuitable 
for ADT (e.g. due to comorbidities) or unwilling to accept ADT (e.g. to preserve their sexual 
health), the recommended treatment is IMRT at a dose of 76-80 Gy or a combination of 
IMRT and brachytherapy. 
 
Localised high-risk PCa: The high risk of relapse outside the irradiated volume 
makes it mandatory to use a combined modality approach, consisting of dose-escalated 
IMRT, possibly including the pelvic lymphatics and long-term ADT. The duration of ADT 
has to take into account performance status, comorbidities, and the number of poor prognostic 
factors.  
 
Locally advanced PCa: T3-4 N0, M0: The standard of care is IMRT combined with 
long term ADT, as it results in better OS [69-71]. The combination is clearly better than 
EBRT or ADT monotherapy [72]. In both high-risk localised and locally advanced disease, 
upfront combination with docetaxel only improves relapse free survival, with no survival 
benefit at 9 years [73]. 
  
Lymph node irradiation 
In men with cN0 PCa, randomised trials have failed to show a benefit from prophylactic 
pelvic nodal irradiation (46-50 Gy) in high-risk cases [74]. In men with cN1 or pN1 the 
outcome of radiotherapy alone is poor, and these patients should receive RT plus long-term 
ADT, as shown by the STAMPEDE trial where the use of radiotherapy improved failure-free 
survival in men with N+ PCa [75]. 
 
Post-operative EBRT after RP 
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Extra-capsular invasion and positive surgical margins are associated with a risk of local 
recurrence and progression. Adjuvant radiotherapy is associated at least with improved 
biochemical progression-free survival in 3 randomised trials [76-78] although only SWOG 
8794 [78] suggested improved OS. Thus, for patients classified as pT3 pN0 with a high risk of 
local failure due to positive margins (highest impact), pT3a or pT3b with a post-operative 
PSA < 0.1 ng/mL, two options can be offered in the framework of informed consent: either 
immediate EBRT to the surgical bed after recovery of urinary function, or monitoring 
followed by early salvage radiotherapy (SRT) before the PSA exceeds 0.5 ng/mL [79]. 
 
Side effects of Definitive Radiotherapy 
The Memorial Sloan-Kettering Cancer Center group has reported data on late toxicity from 
their experience in 1571 patients with T1-T3 disease treated with either 3D-CRT or IMRT at 
doses of between 66 Gy and 81 Gy, with a median follow-up of 10 years [61]. The use of 
IMRT significantly reduced the risk of late grade 2 or higher gastrointestinal (GI) toxicity to 
5% compared to 13% with 3D-CRT. The incidence of grade 2 or higher late genito-urinary 
(GU) toxicity was 20% in patients treated with 81 Gy IMRT vs. 12% with lower doses. The 
overall incidences of late grade 3 toxicity were 1% and 3% for GI and GU toxicity 
respectively.  
 
Systematic review and meta-analysis of observational studies comparing patients exposed or 
unexposed to EBRT in the course of treatment for prostate cancer demonstrate an increased 
risk of developing second cancers for bladder (OR 1.39, 95% CI 1.12-1.71), colorectal (OR 
1.68, 95% CI 1.33-2.12) and rectum (OR 1.62, 95% CI 1.26-2.08) with similar risks over lag 
times of 5 and 10 years. Absolute risks over 10 years are small (1-4%) but should be 
discussed with younger men in particular [80]. 
 
 
Low-dose rate (LDR) brachytherapy uses permanent radioactive seeds implanted 
into the prostate and is an option in those with low-risk disease and selected cases with 
intermediate-risk disease (low volume Gleason 3+4), prostate volume of < 50 cm3 and an 
IPSS ≤ 12 [81]. Up to 85% relapse-free survival at 10 years is demonstrated [82]. LDR as a 
boost with EBRT can be used to dose escalate radiation in intermediate and high-risk patients. 
Although seen as a low impact treatment modality some patients experience significant 
urinary complications following implantation, such as urinary retention (1.5-22%), need for 
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post-implantation TURP (8.7% of cases), and urinary incontinence (0-19%) [83]. Previous 
TURP for BPH increases the risk of post-implantation incontinence and urinary morbidity. 
Erectile dysfunction develops in about 40% of patients after 3-5 years 
 
High-dose rate (HDR) brachytherapy uses a radioactive source temporarily 
introduced into the prostate to deliver radiation. HDR brachytherapy can be delivered in 
single or multiple fractions and is often combined with EBRT of at least 45 Gy as a method of 
dose escalation in intermediate or high-risk PCa. Quality-of-life changes are similar to high-
dose EBRT alone [84]. HDR brachytherapy as monotherapy has been pioneered in a small 
number of centres with low published toxicity and high biochemical control rates, but 
currently mature data is not available on the optimal treatment schedule [85].   
 
  
Alternative local treatment options  
Besides RP, EBRT and brachytherapy, other modalities have emerged as therapeutic options 
in patients with clinically localised PCa. However patients with a life expectancy > 10 years 
should be fully informed that there are limited data on the long-term outcome for cancer 
control beyond 10 years. Recently, focal therapy has been developed, with the aim to ablate 
tumours selectively whilst sparing the neurovascular bundles, sphincter and urethra. Based on 
the available data [86], it should still be considered as fully experimental. 
 
 Cryosurgery might be considered for patients with an organ-confined PCa or minimal 
tumour extension beyond the prostate, prostate volumes < 40 mL, PSA < 20 ng/mL, and GS 
of < 7.  
A systematic review compared Cryotherapy vs. RP and EBRT [86]. Data from 3995 
patients across 19 studies were included. In the short-term, there was conflicting evidence 
relating to cancer-specific outcomes. The 1-year disease-free survival was worse for 
cryotherapy than for either EBRT or RP. None of the other cancer-specific outcomes 
including OS, showed any significant differences. The high risk of bias across studies 
precludes any clear conclusions. 
 
High-intensity focused ultrasound of the prostate (HIFU) has been compared in a 
systematic review [86] to RP and EBRT as primary treatment for localised PCa. Data from 
4000 patients across 21 studies were included. HIFU had a significantly worse disease-free 
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survival at 1 year compared to EBRT. The differences were no longer significant at 3 years. 
The biochemical result was in contrast to OS at 4 years, which was higher when using HIFU. 
The quality of the evidence was poor, due to high risks of bias across studies precluding any 
clear conclusion.  
 
The overall PCa guidelines are summarised in Table 8. 
Table 8: Summary of the main findings regarding treatment of non-metastatic PCa 
 
Recommendation LE GR 
Management decisions should be made after all treatments have been discussed in a 
multidisciplinary team 
4 A* 
Offer RP to patients with low- and intermediate-risk PCa and a life expectancy > 10 
years, 
1b  A 
Nerve-sparing surgery may be attempted in pre-operatively potent patients with low 
risk for extracapsular disease (T1c, GS < 7 and PSA < 10 ng/mL, or refer to Partin 
tables/nomograms). 
2b B 
In intermediate- and high-risk disease, use mpMRI as a decision tool to select patients 
for nerve-sparing procedures  
2b B 
Offer RP in a multimodality setting to patients with high-risk localised PCa and a life 
expectancy of > 10 years. 
2a A 
Offer RP in a multimodality setting to selected patients with locally advanced (cT3a) 
PCa, and a life expectancy > 10 years. 
2b B 
Offer RP in a multimodality setting to highly selected patients with locally advanced 
PCa (cT3b-T4 N0 or any T N1). 
3 C 
Do not offer NHT before RP. 1a  A 
Do not offer adjuvant HT for pN0. 1a A 
Offer adjuvant ADT for node-positive (pN+). 1b A 
Offer EBRT using IMRT to all risk groups 2a A 
In patients with low-risk PCa, without a previous TURP, with a good IPSS and a 
prostate volume of < 50ml, offer LDR brachytherapy 
2a A 
In low risk PCa, use a total dose of 74 to 78 Gy 1a A 
In intermediate- risk PCa use a total dose of 76-78 Gy, in combination with short-term 
ADT (4-6 mo). 
1b A 
In patients with high-risk localised PCa, use a total dose of 76-78 Gy in combination 
with long-term ADT (2-3 yr).   
1b A 
In patients with locally advanced cN0 PCa, offer radiotherapy in combination with 
long-term ADT (2-3 yr). 
1a A 
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In patients with cN1 PCa offer pelvic external irradiation in combination with 
immediate long-term ADT. 
2b B 
Offer adjuvant ADT for pN1 after ePLND. 1b A 
Discuss adjuvant ADT with additional radiotherapy for pN1 after ePLND 2b A 
Offer oďserǀatioŶ ;eǆpeĐtaŶt ŵaŶageŵeŶtͿ for pNϭ after eLND ǁheŶ ч Ϯ Ŷodes shoǁ 
microscopic involvement with a PSA < 0.1 ng/mL and absence of extranodal extension 
2b B 
In patients with pT3N0M0 PCa and an undetectable PSA following RP, discuss adjuvant  
EBRT because it improves at least biochemical-free survival 
1a A 
Inform patients with pT3N0M0 PCa and an undetectable PSA following RP about 
salvage irradiation as an alternative to adjuvant irradiation when PSA increases 
2b A 
Only offer cryotherapy and HIFU within a clinical trial 3 B 
Do not offer focal therapy of the prostate outside a clinical trial 3 A 
 
ADT = androgen-deprivation therapy; AS = active surveillance; DFS = disease-free survival; EBRT = external 
beam radiotherapy; ePLND = extended lymph node dissection; GS = Gleason score; HIFU = high-intensity 
focused ultrasound; HT = hormone therapy; IPSS = International Prostate Symptom Score; mpMRI = 
multiparametric magnetic resonance imaging; NHT = neoadjuvant hormonal therapy; OS = overall survival; PCa = 
prostate cancer; PSA = prostate-specific antigen; RP = radical prostatectomy; TURP = .transurethral resection of 
prostate. 
 
 
Summary 
The present text represents a summary of the 2016 EAU Prostate cancer guidelines. 
For more detailed information and a full list of references, refer to the full-text version (ISBN 
978–90–79754–71–7), which are available at the EAU Web site 
(http://uroweb.org/guideline/prostate-cancer/). 
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